A Randomized, Double Blind, Placebo-controlled, Dose-escalation, Crossover Study to Compare and Evaluate the Pharmacokinetics and Safety of 'CG-745 IV' Intravenous Formulation and 'CG-750' Capsule Formulation in Healthy Male Adults
Latest Information Update: 18 Aug 2022
At a glance
- Drugs CG-750 (Primary) ; Ivaltinostat (Primary)
- Indications Cancer; Fibrosis; Myelodysplastic syndromes; Pancreatic cancer
- Focus Pharmacokinetics
- Sponsors CrystalGenomics
Most Recent Events
- 28 Jun 2022 Results presented at the 15th Congress of the European Association for Clinical Pharmacology and Therapeutics (EACPT) 2022
- 03 May 2022 New trial record